Trial Profile
A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Pilaralisib (Primary)
- Indications Endometrial cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Sanofi
- 02 Apr 2022 This trial has been completed in France, according to European Clinical Trials Database record.
- 08 Jan 2013 Status changed from recruiting to discontinued, according to a Sanofi media release.
- 20 Jun 2012 Planned End Date changed from 1 Mar 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.